JAMA
September 10, 2019, Vol 322, No. 10, Pages 903-1022
http://jama.jamanetwork.com/issue.aspx

CAR T-Cell TherapyA Microcosm for the Challenges Ahead in Medicare
Caron Jacobson, MD; Amy Emmert, MScPH; Meredith B. Rosenthal, PhD
JAMA. 2019;322(10):923-924. doi:10.1001/jama.2019.10194
This Viewpoint discusses existing mechanisms of Medicare reimbursement for chimeric antigen receptor (CAR) T-cell therapy, which at US $375 000 to $475 000 per treatment is prohibitively expensive, and proposes ways to mitigate the challenges of covering the therapy appropriately and equitably for those who need it while realistically managing cost constraints.